Lipid management

What clogs your arteries is not one cholesterol reading but the lifetime dose of cholesterol-carrying particles they have been exposed to — so lowering it early pays far more than lowering it late, and counting the particles tells you more than the usual LDL number. Statins work, most of the muscle pain blamed on them is not caused by the drug, and the much-anticipated Lp(a) drugs have not yet shown they prevent anything.

Add apoB to your blood tests and get one lifetime Lp(a) test, start taking your LDL seriously in your 30s and 40s rather than your 60s, and if your risk is borderline or intermediate and you can't decide about a statin, a coronary calcium scan is the tie-breaker. If a statin seems to give you muscle aches, test that with your doctor before giving it up.

Why the lifetime dose matters more than today's number

Atherosclerosis behaves like a running total, not a snapshot.[1] Each cholesterol-carrying particle that crosses the artery wall has some chance of getting stuck there; over decades, stuck particles oxidise, draw in immune cells and build plaque. So the damage depends on how high your particle count has been multiplied by how long it has been that high.

A US study that enrolled about 5,000 adults aged 18 to 30 and followed them for a median 16 years after they turned 40 measured this directly. Cardiovascular risk tracked each person's cumulative LDL exposure over the years, independent of any single reading, and the same total built up at a younger age did more harm than the same total built up later.[2]

Genetics points the same way. People born with variants that keep their LDL low for life get up to three times as much risk reduction per unit of LDL lowered as people who start a statin in midlife.[3] Plaque you never grow is easier to prevent than plaque you already have, which makes lipids a problem for your 30s and 40s, not one to solve at 55.

Count the particles: apoB versus LDL cholesterol

Every particle that can build plaque — LDL, its larger cousins, and Lp(a) — carries exactly one molecule of a protein called apolipoprotein B (apoB), so measuring apoB counts the particles. LDL cholesterol (LDL-C), the standard number, measures only how much cholesterol sits inside one kind of particle, and that amount varies from person to person.[4] When particles are small and cholesterol-poor, as in insulin resistance, LDL-C can look reassuring while the count is high. ApoB predicts cardiovascular risk at least as well as LDL-C, and better when the two disagree.

The mismatch is common. In a UK study of 375,544 adults, about one in five had an apoB clearly out of line with their LDL-C; where apoB was the higher of the two, the risk of major cardiovascular events ran about 6–11% higher, regardless of LDL-C level.[5]

The 2026 US cholesterol guideline (from the American College of Cardiology and American Heart Association, ACC/AHA) gives apoB a supporting role: it is reasonable to measure once LDL-C and non-HDL-C goals are met on treatment, to decide whether to push further — especially with heart disease, type 2 diabetes or high triglycerides — and may be reasonable before treatment to refine risk.[6] For a baseline workup, an apoB test probably tells you more than the LDL-C on the same panel; that acting on it improves outcomes is the less certain part, resting on observational studies.

Working out your risk: the calculator and the calcium scan

US guidelines now estimate 10-year risk with the PREVENT equations, which replaced the older Pooled Cohort Equations,[7] add kidney function, and drop race.[8] Risk calculators like PREVENT rank people well, but their absolute estimates can drift: PREVENT gives lower estimates than the old tool, and it may understate risk in people who never start a statin. In 193,885 Californian adults it matched overall risk, but among those who stayed off statins, 8.2% of people with a predicted risk of 5% to under 7.5% had an event, against an average prediction of 6.1%.[9] Who started a statin wasn't random, so part of that gap may reflect who chose treatment, and a larger validation across 30 health systems found PREVENT well calibrated overall.[10] Treat a borderline score as a starting point, not a verdict — especially with a strong family history or long-standing high LDL — and at intermediate risk the guideline generally recommends a statin anyway.

When the decision is still uncertain at intermediate (5% to under 10%) or selected borderline (3% to under 5%) risk, the guideline recommends a coronary artery calcium (CAC) scan — a quick, non-contrast CT — in men from 40 and women from 45.[11] Any calcium means plaque is already there and is a reason to start treatment, particularly at a score of 100 or more. The LDL-C goal tightens with the score: under 100 mg/dL (2.6 mmol/L) for a small score, under 70 mg/dL (1.8 mmol/L) from 100 or at or above the 75th percentile for age, sex and race, and under 55 mg/dL (1.4 mmol/L) from 1,000.

A zero buys time, but less than is often claimed. In a large multi-ethnic US study, the "warranty" lasted about 3 to 7 years, and diabetes cut it to about 3 years in men and 4 in women.[12] So the guideline treats deferring a statin on a zero score as reasonable only for adults who prefer to avoid medication and have none of: familial hypercholesterolemia or an LDL-C of 190 mg/dL (4.9 mmol/L) or more, diabetes after 40, current smoking, or a strong family history of early heart disease — and even then it advises rescanning in 3 to 7 years.[13]

The scan predicts well, but no randomised trial has yet shown that scanning people leads to fewer heart attacks or deaths; so far it has modestly improved cholesterol and perhaps statin adherence.[14]

What statins deliver, and what they cost

Statins block the liver's cholesterol factory, which makes liver cells pull more LDL particles out of the blood. In people without heart disease, three large trials showed the payoff:

  • In 17,802 healthy adults with normal LDL-C but raised inflammation, rosuvastatin 20 mg cut cardiovascular events by 44%; the trial was stopped early at 1.9 years.[15]
  • In 12,705 intermediate-risk adults, rosuvastatin 10 mg cut heart attack, stroke and cardiovascular death by 24% over 5.6 years — about one event prevented for every 91 people treated.[16]
  • In 7,832 Japanese adults with high cholesterol, low-dose pravastatin cut coronary heart disease by a third (66 against 101 events) over about five years, despite lowering LDL-C by only 18%, with no excess of cancer or other serious harms.[17]

The benefit builds with time. Across eight trials in adults aged 50 to 75, about 0.3 major events were prevented per 100 people treated at one year, 1.3 at three years and 2.5 at five; only one of the eight found fewer deaths overall.[18] The payoff depends on staying on the drug. For people over 70, a 2026 trial of 9,971 adults without heart disease, diabetes or dementia found atorvastatin 40 mg cut major cardiovascular events by about 30% over a median 5.9 years, but did not lengthen survival free of dementia or disability.[19]

The diabetes cost is real. JUPITER recorded about 25% more diabetes diagnoses on rosuvastatin (270 cases against 216); the extra cases were all in people who already had a risk factor for it.[20] Pooled blinded trials show it is a dose-dependent effect of the whole class: low- or moderate-intensity statins raised new diagnoses by about 10%, high-intensity ones by about 36%. About 62% of the extra cases were in people whose blood sugar was already in the top quarter, and the trials' overall reduction in heart attacks and strokes already counts any cardiovascular cost.[21] In HOPE-3, the 10 mg dose produced no diabetes excess but slightly more muscle symptoms (5.8% vs 4.7%) and cataract surgery (3.8% vs 3.1%); a substudy in people 70 and over found no effect on thinking.[22]

Beyond muscle and diabetes, blinded trials of 123,940 people confirm only small harms: abnormal liver-enzyme results about 41% more often (0.30% against 0.22% of people a year), and slight excesses of urine-test changes and fluid swelling. Memory problems, depression, sleep trouble, nerve damage and sexual dysfunction were no more common, despite appearing on product labels.[23]

Most statin muscle pain is not the statin

Muscle aches are the main reason people stop statins, and real-world reports put them above 10%. Under blinding, the picture changes: across 19 double-blind trials of 123,940 people followed for about four years, 27.1% on a statin and 26.6% on placebo reported muscle pain or weakness — a 3% relative excess, concentrated in the first year and somewhat larger at high doses. More than 90% of the muscle complaints reported on a statin were not caused by it.[24] In another trial, complaints ran at the same rate on atorvastatin and placebo while patients were blinded, but about 40% more often among statin users once they knew what they were taking.[25]

A British trial tested this in the hardest group: 60 adults who had given up statins for good because side effects appeared within two weeks of starting — muscle aches in most of them.[26] Each got 12 monthly bottles in random order — four of atorvastatin 20 mg, four of placebo, four empty — and scored symptoms daily on a 1–100 scale. Empty-bottle months averaged 8.0, statin months 16.3 and placebo months 15.4, statistically indistinguishable from the statin. About 90% of the extra symptoms on the statin were also produced by placebo. Six months later, half of the 60 were taking a statin again.

That is one small trial in people who had already quit, so the finding is probable rather than proven. It does not mean statin muscle damage is fake: true muscle breakdown with raised creatine kinase is documented, if rare. It means the typical ache that makes people stop is mostly not the drug, and a structured personal trial got half of them back on treatment. CoQ10 is often tried for statin aches — statins do lower it — but the randomised evidence is mixed, and against that placebo background any "response" is hard to credit; see CoQ10.

When a statin isn't enough

Lowering cholesterol-carrying particles works whichever drug does it: drugs that clear them by different routes produce benefit in proportion to how far they lower them. That is why the old idea of special non-cholesterol statin effects is largely settled. Not every cholesterol drug qualifies, though — the drug evacetrapib cut LDL-C by about 31% and prevented no events,[27] and genetic evidence suggests benefit follows the fall in apoB particles rather than in LDL cholesterol as such.[28]

Ezetimibe blocks cholesterol absorption in the gut. Added to a statin in 18,144 people after a heart attack or unstable angina, it took LDL-C from about 70 to 54 mg/dL (1.8 to 1.4 mmol/L) and cut cardiovascular events from 34.7% to 32.7% over 7 years — about 2 fewer per 100 people — with no extra muscle, gallbladder, liver or cancer problems.[29]

Bempedoic acid blocks the same cholesterol-making pathway further upstream and is switched on mainly in the liver, so it is designed to spare muscle.[30] In 13,970 people who could not or would not take statins because of side effects, it cut major cardiovascular events by 13% and heart attacks by 23%, but had no significant effect on stroke, cardiovascular death or death overall.[31] It did not raise diabetes (11.1% against 11.5% developed it),[32] and muscle aches were no more common than on placebo.[33] It is a guideline-backed alternative if you cannot take a statin, and an add-on for high-risk patients still above goal — not a swap for a statin you tolerate. Alone it lowers LDL-C by only about 21–24%, against 50% or more for a high-intensity statin,[34] and it has its own side effects: more gout (3.1% vs 2.1%), more gallstones (2.2% vs 1.2%), and small rises in uric acid, creatinine and liver enzymes.[35] European guidance advises caution with any history of gout.[36]

PCSK9 antibodies disable a protein that destroys the liver's LDL receptors, so the liver clears far more particles. Added to statins in 27,564 people with established cardiovascular disease, evolocumab cut LDL-C by 59% (a median 92 down to 30 mg/dL) and major events by 15–20% depending on the definition.[37] Alirocumab did about the same in 18,924 people after an acute coronary event (about 15% fewer events).[38] In 2026 they also proved themselves before a first event: in 12,257 adults with known atherosclerosis or high-risk diabetes, an LDL-C of at least 90 mg/dL, and no previous heart attack or stroke, evolocumab cut coronary death, heart attack or ischaemic stroke by about a quarter over a median 4.6 years (6.2% against 8.0% by five years), with no excess of safety problems.[39]

Very low LDL-C has so far looked safe. In FOURIER's open-label extension, people at a median LDL-C of 30 mg/dL (0.8 mmol/L), followed for up to 8.4 years, had no more serious adverse events, new diabetes, bleeding strokes or memory problems than placebo had in the original trial, and those who started two years earlier had about 20% fewer cardiovascular deaths, heart attacks and strokes.[40] For many people with heart disease, the limit on how low LDL-C goes is cost and access, not the drugs.

Lp(a): an inherited risk with no proven fix yet

About 20% of people — roughly 1.4 billion worldwide — carry enough lipoprotein(a), or Lp(a) to add substantially to their cardiovascular risk.[41] At 125 nmol/L (50 mg/dL), a level about one person in five reaches, risk is about 1.4 times typical; at 250 nmol/L (100 mg/dL) it is about double.[42] Lp(a) is an LDL-like particle with an extra tail, and a causal, inherited driver of both coronary disease and narrowing of the aortic valve.

It is more than 90% genetic and fairly stable from about age 5, though it tends to rise in women at menopause, so one test is usually enough; the 2026 guideline now recommends that every adult have it measured once. Diet and exercise barely move it, and PCSK9 antibodies lower it by roughly 15–30%.[43] Statins don't lower it and may nudge it up by about 1 mg/dL on average, which is no reason to stop one.[44]

The first Lp(a) drug failed its test. Pelacarsen, a monthly injection that lowers Lp(a) by about 72%,[45] was given to 8,323 people with established cardiovascular disease and high Lp(a). Topline results in September 2026 showed it lowered Lp(a) but did not significantly reduce the combined rate of cardiovascular death, heart attack, stroke and urgent procedures to restore blood flow to the heart; full data are still to come.[46] So no trial has yet shown that lowering Lp(a) prevents heart attacks or strokes, and no drug is approved for it. Three more drugs cut Lp(a) by roughly 70% to more than 95% in early trials, but their outcome trials are not expected to finish before 2028–2031. A high Lp(a) is still worth knowing, because it is a reason to control everything else harder.[47]

The targets the 2026 guideline sets

The 2026 ACC/AHA guideline brought back numeric goals for LDL-C and non-HDL-C, used alongside the percentage fall in LDL-C to decide when to step up treatment:[48]

  • <100 mg/dL (2.6 mmol/L) at borderline or intermediate risk, once a statin has been started.
  • <70 mg/dL (1.8 mmol/L) at high risk (10% or more) without cardiovascular disease, and for established cardiovascular disease that is not very high risk.
  • <55 mg/dL (1.4 mmol/L) for very-high-risk cardiovascular disease (two or more major events, or one plus at least two high-risk conditions), or cardiovascular disease together with chronic kidney disease (stage 3 or worse) — which covers most people who have had a heart attack or stroke. It is optional for other people with cardiovascular disease.

Treatment starts with the highest tolerated statin; ezetimibe, a PCSK9 antibody or bempedoic acid is added according to how much further LDL-C must fall, and for very-high-risk patients ezetimibe and/or a PCSK9 antibody should be added. Inclisiran, a twice-yearly injection that also blocks PCSK9, is second-line because its outcome trials have not reported.

Screening starts earlier, to catch familial hypercholesterolemia (FH), an inherited cause of very high LDL: a lipid profile for every child at 9–11, from age 2 if a close relative has FH, very high cholesterol or early heart disease, and for adults from 19 and at least every 5 years. In young adults, drug treatment should be considered early at an LDL-C of 160 mg/dL (4.1 mmol/L) or more, or with a strong family history.

What to actually do

  1. Add apoB to your blood tests and get one lifetime Lp(a) test. Both are cheap and add what a standard panel misses; they belong on the midlife lab panel.
  2. Start early. Lowering LDL in your 30s and 40s does far more for lifetime risk than the same lowering in your 60s, though late is still well worth it.
  3. Use the calcium scan to break a tie, not as a routine test, and don't treat a zero as a reason to wait if you have any of the higher-risk conditions above.
  4. Eat a Mediterranean pattern, and target LDL directly. In a large Spanish trial, older adults at high risk who ate a Mediterranean diet with extra olive oil or nuts had about 30% fewer heart attacks, strokes and cardiovascular deaths, a result that survived the trial's 2018 retraction and re-analysis but no longer rests on fully clean randomisation,[49] and a trial in people with heart disease found a similar benefit against a low-fat diet.[50] Its effect on LDL itself is modest. To lower LDL, replace saturated fat (red meat, butter, full-fat dairy, coconut and palm oil) with unsaturated fats and eat more fibre, nuts and legumes; a "portfolio" diet that also added soy protein and plant-sterol margarine lowered LDL-C by about 26 mg/dL (0.67 mmol/L).[51] See Dietary patterns and Foods to limit.
  5. Don't count on supplements. In one short head-to-head trial, fish oil, garlic, cinnamon, turmeric, plant sterols and red yeast rice did not lower LDL-C significantly more than placebo; a low-dose statin did.[52]
  6. If a statin seems to hurt, test it before quitting. Switching statins, lowering the dose, alternate-day dosing, or a blinded trial with your own doctor often keeps you on treatment.
  7. If you truly can't take a statin, ask about bempedoic acid, and mention any history of gout. If LDL-C stays high on the most statin you tolerate (or statin plus ezetimibe), ask about a PCSK9 antibody.
  8. If your Lp(a) is high, treat everything else harder. The National Lipid Association advises earlier and more intensive control of other risk factors, mainly lowering LDL-C with lifestyle and, when overall risk is high, drugs — and testing your parents, siblings and children.[53] With cardiovascular disease and LDL-C above goal on your top statin dose, the 2026 guideline specifically recommends adding a PCSK9 antibody.
  9. The rest of the risk frame still counts. Don't smoke; manage blood pressure and weight; keep aerobic fitness. See Blood pressure, VO₂ max and Smoking and nicotine.

What's overrated

  • "My LDL is normal, so I'm fine." A normal LDL-C doesn't rule out a high particle count — about one adult in ten has a higher apoB than their LDL-C suggests.
  • Fear of eggs and dietary cholesterol. Eating more cholesterol raises LDL only modestly, and cohort studies mostly find no clear link to heart disease at usual intakes; the American Heart Association advises looking at the overall eating pattern instead.[54] Saturated fat matters more.
  • HDL as a target. Most HDL-raising drugs failed; the one that helped (anacetrapib, about 9% fewer major coronary events) did about what its 18% fall in non-HDL cholesterol predicts, despite doubling HDL.[55] HDL is a marker, not a lever.
  • A yearly cholesterol panel as the whole story. One LDL-C reading says much less than the trajectory, the apoB, the Lp(a) and, when needed, the calcium score together.

Further reading

  • Ference BA, Braunwald E, Catapano AL. The LDL cumulative exposure hypothesis — evidence and practical applications. Nature Reviews Cardiology 2024.[56]
  • Blumenthal RS et al. 2026 ACC/AHA/Multisociety guideline on the management of dyslipidemia. J Am Coll Cardiol 2026;87:2624.[57]
  • Domanski MJ et al. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk — CARDIA. J Am Coll Cardiol 2020.[58]
  • Du Y et al. Impact of LDL-C and Apolipoprotein B Level Discordance and associated Lipoprotein Particle Alterations on Cardiovascular Outcomes in a large primary prevention population. Eur J Prev Cardiol 2025.[59]
  • Yusuf S et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease — HOPE-3. NEJM 2016.[60]
  • Howard JP et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment (SAMSON). J Am Coll Cardiol 2021.[61]
  • Cannon CP et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). N Engl J Med 2015.[62]
  • Nissen SE et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients — CLEAR Outcomes. NEJM 2023.[63]
  • Sabatine MS et al. Evolocumab and clinical outcomes in patients with cardiovascular disease — FOURIER. NEJM 2017.[64]
  • Bohula EA et al. Evolocumab in patients without a previous myocardial infarction or stroke — VESALIUS-CV. N Engl J Med 2026.[65]
  • Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022.[66]
  • Lp(a)HORIZON topline results — pelacarsen did not meet its primary endpoint (Novartis, September 2026).[67]

— § —